HI-6 Dimethanesulfonate (DMS) and Atropine Sulfate Reconstitution Autoinjector Device (RAD) Feasibility Assessment

The Department of National Defence (DND), specifically the Canadian Forces Health Services (CFHS), has a requirement for the services of a Contractor to test and evaluate the feasibility of manufacturing HI-6 DMS and atropine sulfate drug products in a reconstitution autoinjector device (RAD). The scope of this requirement is to conduct a feasibility assessment using an existing prototype of a RAD with the configuration of HI-6 DMS in the dry chamber (500 mg +/- 25%) and 1 mL atropine (2 mg/mL) in the liquid chamber. The work will involve the following: • Project Management. • Analytical Method Development. • Material Processing and Performance Assessments. • Mixing and Drug Delivery Model. • Sterilization Impact Assessment.